Глюкокортикоидный остеопороз: диагностика, профилактика и лечение
https://doi.org/10.14412/1995-4484-2014-423-429
Аннотация
В лекции приведены сведения об эпидемиологии и патогенезе глюкокортикоидного остеопороза (ГК-ОП). Представлены последние критерии диагностики, модифицированный алгоритм FRAX оценка 10-летней вероятности остеопоретического перелома) в зависимости от принимаемой дозы глюкокортикоидов (ГК), данные последних клинических рекомендаций по лечению и профилактике ГК-ОП, особенностям ведения больных в зависимости от возраста пациента.
Об авторе
Н. В. Торопцова
ФГБНУ Научно-исследовательский институт ревматологии им. В.А. Насоновой, Москва
Россия
Россия
заведующая лабораторией остеопороза отдела метаболических заболеваний костей и суставов с центром профилактики остеопороза Минздрава России
ФГБНУ НИИР им. В.А. Насоновой, докт. мед. наук
Список литературы
1. Cushing H. The basophilic adenomas of the pituitary body and their clinical manifestations (pituitary asophilism). Bull Johns Hopkins Hosp. 1932;(1):137–92.
2. Kanis JA, Johansson H, Oden A, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res. 2004;19(6):893–9. Epub 2004 Jan 27. DOI:http://dx.doi.org/10.1359/JBMR.040134.
3. Diez-Perez A, Hooven FH, Adachi JD, et al. Regional differences in treatment for osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone. 2011;49(3):493–8. DOI: 10.1016/j.bone.2011.05.007. Epub 2011 May 14.
4. Angeli A, Guglielmi G, Dovio A, et al. High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. Bone. 2006;39(2):253–9. Epub 2006 Mar 30. DOI: http://dx.doi.org/10.1016/j.bone.2006.02.005.
5. Van Staa TP, Leufkens HG, Abenhaim L, et al. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford). 2000;39(12):1383–9. DOI: http://dx.doi.org/10.1093/rheumatology/39.12.1383.
6. Steinbuch M, Youket TE, Cohen S. Oral glucocorticoid use is associated with an increased risk of fracture. Osteoporos Int. 2004;15(4):323–8. DOI: http://dx.doi.org/10.1007/s00198-003- 1548-3. Epub 2004 Feb 5.
7. Van Staa TP, Laan RF, Barton IP, et al. Bone density threshold and ther predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum. 2003 Nov;48(11):3224–9. DOI: http://dx.doi.org/10.1002/art.11283.
8. Hofbauer LC, Gori F, Riggs BL, et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoids-induced osteoporosis. Endocrinology. 1999;140(10):4382–9.
9. Gulko PS, Mulloy AL. Glucocorticoid-induced osteoporosis: pathogenesis, prevention and treatment. Clin Exp Rheumatol. 1996;14(2):199–206.
10. Лесняк ОМ, Баранова ИА, Торопцова НВ. Клинические рекомендации: диагностика, профилактика и лечение глюкокортикоидного остеопороза у мужчин и женщин 18 лет и старше. Ярославль: Литера; 2013. 48 с. [Lesnyak OM, Baranova IA, Toroptsova NV. Klinicheskie rekomendatsii: iagnostika, profilaktika i lechenie glyukokortikoidnogo osteoporoza u muzhchin i zhenshchin 18 let i starshe [Clinical recommendations: diagnostics, prevention and treatment of glucocorticoid osteoporosis at men and women of 18 years also is more senior]. Yaroslavl': Litera; 2013. 48 p.]
11. Kanis JA, Johansson H, Oden A, McCloskey E. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int. 2011;22(3):809–16. DOI: 10.1007/s00198-010-1524-7. Epub 2011 Jan 13.
12. Adachi JD, Saag KG, Delmas PD, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, lacebocontrolled extension trial. Arthritis Rheum. 2001;44(1):202–11. DOI: http://dx.doi.org/10.1002/1529-0131(200101)44:1%3C202::AID-ANR27%3E3.0.CO;2-W.
13. De Nijs RN, Jacobs JW, Lems WF, et al.; STOP Investigators. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med. 2006;355(7):675–84. DOI: http://dx.doi.org/10.1056/NEJMoa053569.
14. Reid DM, Hughes RA, Laan RF, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroidinduced osteoporosis in men and women: a randomized trial. European Corticosteroid- Induced Osteoporosis Treatment Study. J Bone Miner Res. 2000;15(6):1006–13. DOI: http://dx.doi.org/10.1359/jbmr.2000.15.6.1006.
15. Wallach S, Cohen S, Reid DM, et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int. 2000;67(4):277–85. DOI: http://dx.doi.org/10.1007/s002230001146.
16. Reid DM, Devogelaer JP, Saag K, et al.; HORIZON investigators. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoidinduced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2009;373(9671):1253–63. DOI: 10.1016/S0140-6736(09)60250-6.
17. Saag KG, Shane E, Boonen S,et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007;357(20):2028–39. DOI: http://dx.doi.org/10.1056/NEJMoa071408.
18. Saag KG, Zanchetta JR, Devogelaer JP, et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, doubleblind, controlled trial. Arthritis Rheum. 2009;60(11):3346–55. DOI: 10.1002/art.24879.
19. Compston J, Reid DM, Boisdron J, et al.; Group for the Respect of Ethics and Excellence in Science. Recommendations for the registration of agents for prevention and treatment of lucocorticoid- induced osteoporosis: an update from the Group for the Respect of Ethics and Excellence in Science. Osteoporos Int. 2008;19(9):1247–50. DOI: 10.1007/s00198-008-0670-7. Epub 2008 Jul 5.
20. De Nijs RN, Jacobs JW, Lems WF, et al.; Investigators STOP. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med. 2006;355(20):675–84. DOI: http://dx.doi.org/10.1056/NEJMoa053569.
21. De Nijs RN, Jacobs JW, Algra A, et al. Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: a review with metaanalysis of randomized controlled trials including organ transplantation studies. Osteoporos Int. 2004 Aug;15(8):589–602. DOI: http://dx.doi.org/10.1007/s00198-004-1614-5.
22. Roux C, Reid DM, Devogelaer JP, et al. Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis. Osteoporos Int. 2011;23(3):1083–90. DOI: 10.1007/s00198-00011-01800-00191.
23. Langdahl BL, Marin F, Shane E, et al. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status. Osteoporos Int. 2009;20(12):2095–104. DOI: 10.1007/s00198-009-0917-y. Epub 2009 Apr 7.
24. Yeap SS, Fauzi AR, Kong NC, et al. A comparison of calcium, calcitriol, and alendronate in corticosteroid-treated premenopausal patients with systemic lupus erythematosus. J Rheumatol. 2008;35(12):2344–7. DOI: 10.3899/jrheum.080634. Epub 2008 Nov 1.
Рецензия
Для цитирования:
Торопцова Н.В. Глюкокортикоидный остеопороз: диагностика, профилактика и лечение. Научно-практическая ревматология. 2014;52(4):423-429. https://doi.org/10.14412/1995-4484-2014-423-429
For citation:
Toroptsova N.V. GLUCOCORTICOID-INDUCED OSTEOPOROSIS: DIAGNOSIS, PREVENTION, AND TREATMENT. Rheumatology Science and Practice. 2014;52(4):423-429. (In Russ.) https://doi.org/10.14412/1995-4484-2014-423-429
Просмотров:
1335
Послать статью по эл. почте 